Groundbreaking neurostimulation technology offers hope and healing for difficult-to-manage pain. Chronic low back pain, a formidable foe causing disability and soaring healthcare costs, now faces a ...

DUBLIN--(BUSINESS WIRE)--Mainstay Medical today announced that the United States Centers for Disease Control and Prevention (CDC) has designated an International Classification of Diseases, Tenth ...

Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...

MRI shows selective psoas and rectus atrophy with reduced trunk strength in chronic low back pain, suggesting functional imbalance.

Mainstay Medical’s Reactiv8 restorative neurostimulation device for chronic lower back pain earned favorable coverage from Blue Cross Blue Shield of North Dakota, according to a Feb. 6 news release.